在COVID-19后的流行病中,抗化物耐药的Mycoplasma pneumoniae感染的反弹:一项描述性研究
Fan-Fan Xing1, Kelvin Hei-Yeung Chiu2, Chao-Wen Deng1
1Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.
Antibiotics (Basel, Switzerland)
|March 27, 2024
概括
包括SARS-CoV-2和Mycoplasma pneumoniae在内的呼吸道感染在流行病控制放松后反弹. 菌性肺炎感染造成了严重的医疗负担,并观察到特定的突变.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 公共卫生 公共卫生
背景情况:
- 疫情后的呼吸道感染控制措施的复苏仍然不清楚.
- 了解常见的呼吸道病原体的动态对于公共卫生准备至关重要.
研究的目的:
- 在大流行控制放松后分析呼吸道病毒和Mycoplasma pneumoniae的反弹模式.
- 研究这些感染的临床和微生物特征.
- 为了识别Mycoplasma pneumoniae中的抗菌素耐药性模式.
主要方法:
- 从1月到2023年11月在教学医院进行前性研究.
- 使用抗原,核酸放大和目标下一代测序 (tNGS) 进行呼吸道病毒和Mycoplasma pneumoniae的测试.
- 分析每月阳性测试率,临床数据和微生物学发现,包括遗传突变.
主要成果:
- 随着SARS-CoV-2的快速反弹,Mycoplasma pneumoniae的反弹速度较慢,间隔5个月.
- 在6个月内,Mycoplasma pneumoniae造成了4094例严重的医疗负担.
- 患有Mycoplasma pneumoniae的成年人表现出疲劳和并发症;儿童的发烧和并发症较高.
- 85%的Mycoplasma pneumoniae病例具有23rRNA基因突变,主要是A2063G,与更长的恢复时间有关.
结论:
- 在流行病后的控制中发生了Mycoplasma pneumoniae延迟但显著的反弹.
- 肺炎菌构成了相当大的负担,特别是普遍存在的宏类抗药性突变.
- 没有发现需要进一步调查的不寻常或不明原因的呼吸道感染模式.
相关概念视频
01:30Pneumonia I: Introduction
233
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
233
01:30Pneumonia III: Complications and Assessment
206
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
206
01:28Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324
01:29Pneumonia II: Pathophysiology
262
The pathophysiology of pneumonia involves the following steps:
262